 Home > Active Ingredient News > Drugs Articles > JPM Conference 2023! BeiGene, Hengrui, Rongchang, Innovent and Ascentage and other Chinese new drug R&D companies were unveiled

JPM Conference 2023! BeiGene, Hengrui, Rongchang, Innovent and Ascentage and other Chinese new drug R&D companies were unveiled

 Last Update: 2023-02-02
 Source: Internet
 Author: User

Tags

anti ssa test

what saliva drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

41st J.
P.
Morgan Healthcare Annual Meeting Conference, hereinafter referred to as JPM Conference) grandly opened
on January 9, 2023 Pacific Time.
The JPM Conference will be held in San Francisco until January 12
.
According to the schedule and company press releases published on the JPM conference website, many Chinese new drug R&D companies will attend the conference
.
In this article, we will share some of the basic information of these companies for the reader's reference
only.
(Reply to "JPM" on the medical Guanlan WeChat public account to get the detailed schedule of this meeting).

.
JPM

BeiGene

Presentation: January 9, 1:30 p.
m.
PT

Founded in 2010, BeiGene is focused on developing and commercializing innovative, affordable anti-tumor drugs, John V.
Mr.
Oyler and Dr.
Xiaodong Wang are co-founders
.
According to the company's website, its drug pipeline and commercialization portfolio is expected to cover 80% of the world's cancer types, with 90 ongoing or planned clinical trials, including more than 30 pivotal or potential registration trials
in more than 45 regions.
At present, BeiGene has approved three self-developed core products for commercialization, namely the next-generation BTK selective inhibitor zebratinib, the anti-PD-1 monoclonal antibody tislelizumab, and the PARP inhibitor pamiparib
.
Through external cooperation, the company has introduced 8 products, including the IL-6 antagonist stuximab, bispecific T cell adapter (BiTE), and berintoumab, which have been launched
in China.

John V.
Oyler), Dr.
Wang Xiaodong, has approved the commercialization of 3 self-developed core products, and 8 products have been launched in China through external cooperation

Zai Lab

Presentation: January 10, 9:00 a.
m.
Pacific Time

Speaker: Dr.
Ying Du, Founder, Chairman and CEO of Zai Lab

Zai Lab (Zai Lab) was founded in 2014 by Dr.

Ying Du as the founder, chairman and chief executive officer (CEO).
The company focuses on providing patients in China and around the world with innovative drugs for the treatment of oncology, autoimmune diseases, infectious diseases and central nervous system diseases, and has established a rich product pipeline
.
At present, Zai Lab's pipeline has approved 4 products, namely the PARP inhibitor niraparib, the tumor field therapy device EPDUN and Optune Lua, KIT/PDGFRα kinase switch regulatory inhibitor repatinib, a novel antibiotic omarcycline
tosylate.
In addition, a number of the company's products are in the late stage of development, among which FcRn antagonist Agamod α injection and new anti-infective drug sulbactam-durlobactam have been declared for marketing
in China.

Dr.
Ying Du currently has 4 products approved for marketing in Zai Lab's pipeline and many products are in the late stage of development

Legendary creatures

Presentation time: January 10, 2:15 p.
m.
Pacific Time

Legendary creatures (Legend Biotech) was established in 2014 with Dr.
Ying Huang as CEO and Dr.
Guowei Fang as Chief Scientific Officer.

The company is committed to developing potential cell therapies
for refractory diseases such as hematologic tumors and solid tumors.
Among them, the legendary creature and Johnson (Johnson & Johnson's BCMA developed in partnership with Janssen CAR-T therapy cedarchicel has been approved for marketing in the United States, Japan, the European Union and other places for the treatment of multiple myeloma
.
In December 2022, the new drug application of the drug in China was also accepted
.
In addition, Legend Biologics has a number of autologous cell therapies in its pipeline entering the clinical development stage, targeting Claudin 18.
2, CD19/CD22/CD22, GPC3, DLL3, etc
.

Dr.
Ying Huang, Dr.
Guowei Fang, BCMA CAR-T therapy cedarchicel has been approved for marketing in the United States, Japan, the European Union and other places, and a number of autologous cell therapies have entered the clinical development stage

Insilico

Presentation: January 1, 10:5 p.
m.
PT

Presentation time: January 10, 5:00 p.
m.
Pacific Time, USA

Speaker: Dr.
Alex Zhavoronkov, founder and CEO of Insilico

Insilico Medicine was founded in 2014 by Alex Dr.

Zhavoronkov.
It is a clinical-stage drug discovery company driven by end-to-end artificial intelligence (AI), focusing on cancer, fibrotic diseases, immune diseases, central nervous system diseases, aging-related diseases, and more
.
At present, Insilico has reached Pharma.
AI-related cooperation
with 9 global pharmaceutical companies, including Sanofi.
The company has more than 30 self-developed pipelines, including 3CL protease inhibitors, "synthetically lethal" anti-tumor therapies targeting MAT2A and USP1, respectively
.
Among them, the fastest progress of anti-fibrosis projects has entered the phase 1 clinical trial stage in New Zealand and China
.
At this JPM conference, Alex Dr.
Zhavoronkov will share the progress
of the 6th generation intelligent robot laboratory and the company's IPF project.

Alex Dr.
Zhavoronkov has more than 30 self-developed pipelines, Alex Dr.
Zhavoronkov will share the progress of the 6th generation intelligent robot laboratory and the company's IPF project

Ascentage Pharmaceutical

Presentation: January 11, 8:30 a.
m.
Pacific Time

Presentation time: January 11, 8:30 a.
m.
Pacific Time, USA

Speaker: Dr.
Dajun Yang, Chairman and CEO of Ascentage Pharma

Ascentage Pharma) was founded in 2009 by Dr.
Dajun Yang, co-founder, chairman and CEO.

The company is committed to the development of innovative drugs in the therapeutic areas of oncology, hepatitis B and aging-related diseases, and has entered the clinical development stage of 9 class 1 small molecule new drugs in the research pipeline, including inhibitors of key proteins in the apoptosis pathway such as Bcl-2 inhibitors, IAP inhibitors, MDM2-p53 inhibitors, and inhibitors against kinase mutants that appear in cancer treatment
.
In November 2021, orebatinib, a third-generation BCR-ABL inhibitor developed by Ascentage Pharma, was approved for marketing in China for the treatment of drug-resistant chronic myeloid leukemia
.
In addition, Ascentage is conducting more than 50 Phase 1/2 clinical trials
in China, the United States, Australia and Europe.

Dr.
Yang Dajun has entered the clinical development stage of 9 Class 1 small molecule new drugs in the research pipeline, and the third-generation BCR-ABL inhibitor orebatinib has been approved for marketing in China

InnoCare

Presentation: January 11, 8:30 a.
m.
Pacific Time

Speaker: Dr.
Manish Tandon, Vice President of InnoCare Business Development (BD).

Founded in 2015, InnoCare focuses on the development of
Class 1 new drugs in the field of treatment of malignant tumors and autoimmune diseases.
According to InnoCare's financial report for the third quarter of 2022, the company has established a rich product pipeline, of which the new BTK inhibitor orelabrutinib has been approved for two indications in China, and the anti-CD19 monoclonal antibody tafasitamab has been approved for use
in Boao, Hainan.
In addition, InnoCare has more than 10 products in the clinical stage, including BTK inhibitors, anti-CD19 monoclonal antibodies, targeted protein degraders, BCL2 inhibitors, and CD20 x CD3 bispecific antibodies, SHP2 allosteric inhibitors, etc
.

Novel BTK inhibitor orelabrutinib against CD19 monoclonal antibody tafasitamab

3SBio

<>SBio

Presentation: January 11, 9:00 a.
m.
Pacific Time

Presentation: January 11, 9:00 a.
m.
PT

3SBio is committed to improving the quality of life of patients with high-quality
drugs.
According to the public information of 3SBio, the company has more than 30 listed products, covering a variety of therapeutic fields
such as nephrology, oncology, autoimmune diseases, ophthalmology and dermatology.
In 2022, 3SBio also made a series of new developments, including the submission of a marketing application for recombinant human thrombopoietin injection (TPIAO) for primary immune thrombocytopenia (ITP) indications in children in China; The global rights to the anti-PD-1 monoclonal antibody 609A for the development of the combination therapy for tumor-immunotherapy syncrovax are licensed to Syncromune, among others
.

Recombinant human thrombopoietin injection (terbioao) anti-PD-1 monoclonal antibody 609A

Antengene

Presentation: January 11, 9:30 a.
m.
Pacific Time

Presentation: January 11, 9:30 a.
m.
PT

Speaker: Dr.
Jianming Mei, Founder, Chairman and CEO of Antengene

Antengene is a commercialized biopharmaceutical company focused on the development and commercialization
of innovative therapies in the field of hematology and solid tumors.
According to Antengene's public information, since 2017, the company has established a pipeline of 13 clinical and preclinical products, of which 10 products have global rights and 3 products have Asia-Pacific rights
including Greater China.
Antengene has obtained 27 INDs in the U.
S
.
and multiple Asia-Pacific markets and submitted 9 NDAs.
In addition, oral selective nuclear output protein (XPO1) inhibitor celinisol tablets have been approved for marketing in more than 10 countries and regions around the world, including the United States, the European Union, and China
.

Oral selective nuclear output protein (XPO1) inhibitor celiniso tablets

Innovent Biologics

Presentation time: January 11, 10:00 a.
m.
Pacific Time

Presentation: January 11, 10:00 a.
m.
PT

Speaker: Dr.
Dechao Yu, Founder, Chairman and CEO of Innovent Biologics

Innovent (Innovent Biologics) was founded in 2011 and is committed to the research and development
of innovative drugs in the field of major diseases such as oncology, autoimmunity, metabolism, and ophthalmology.
According to a recent press release from Xinda Biologics, the company has established a product pipeline including 36 new drug varieties, and 8 products have been approved for marketing, including anti-PD-1 monoclonal antibody Cindilimab injection, selective FGFR receptor tyrosine kinase inhibitor pemitinib tablets and so on
.
In addition, the company has 2 products in the review of the China National Food and Drug Administration (NMPA), 6 varieties have entered phase 3 or pivotal clinical studies, and 20 products have entered the clinical research stage
.

Anti-PD-1 monoclonal antibody sindilimab injection, selective FGFR receptor tyrosine kinase inhibitor pemitinib tablets

CanSino Biologics

Presentation: January 11, 11:30 a.
m.
Pacific Time

Presentation: January 11, 11:30 a.
m.
PT

Speaker: Dr.
Xuefeng Yu, Chairman and CEO of CanSino Biologics

CanSino Biologics (CanSino Biologics) was founded in 2019 to provide innovative, high-quality, accessible vaccines
to the world.
According to the press release of CanSino Biologics, the company has five innovative vaccine platform technologies, including viral vector vaccine technology, synthetic vaccine technology, protein structure design and VLP assembly technology, mRNA vaccine technology, formulation and drug delivery technology
.
CanSino Biologics has established dozens of vaccine R&D pipelines covering more than ten infectious diseases, including Ebola virus disease vaccine, adenovirus vector new crown vaccine certified by WHO for emergency use, new crown vaccine for inhalation, quadrivalent flow brain conjugate vaccine and bivalent flow brain conjugate vaccine
using CRM197 vector.

Ebola virus disease vaccine

Hengrui Pharmaceutical

Presentation: January 11, 11:30 a.
m.
Pacific Time

Presentation time: January 11, 11:30 a.
m.
Pacific Time

Jiangsu Hengrui Pharmaceuticals His research interests cover oncology, autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory diseases, blood diseases, neurological diseases, etc
.
According to the official website of Hengrui Pharmaceutical, the company has approved 12 innovative drugs for marketing, and more than 60 innovative drugs are under clinical development
.

The company has approved 12 innovative drugs for marketing, and more than 60 innovative drugs are in clinical development

Hengrui Pharmaceutical's approved innovative drugs include: COX-2 inhibitor ericoxib, VEGFR-2 tyrosine kinase inhibitor apatinib mesylate, second-generation long-acting granulocyte colony-stimulating factor (G-CSF) thioperfilgrastine, anti-HER2 targeting drug pyrotinib maleate, PD-1 inhibitor carrelizumab, short-acting GABAa receptor agonist remazolam tosylate, PARP inhibitor fluzoparib, The non-peptide oral thrombopoietin receptor agonist (TPO-RA) haltrombopagola olamine, the CDK4/6 inhibitor dalcilib, the SGLT2 inhibitor hengliflozin, the second-generation AR inhibitor revilumide, and its PI3K delta inhibitor Linplised,
developed in collaboration with Yingli Pharmaceutical.

Erexib mesylate apatinib thioperagrastim maleate, pyrotinib maleate, carrelizumab tosylate, remazolam fluzoleazole palli, halitrombopag, ethanolamine, dalcili, hengliflozin, revilumide limplisade

Remegen Biotechnology

Presentation: January 1, 11:3 p.
m.
PT

Presentation time: January 11, 3:30 p.
m.
Pacific Time, USA

Founded in 2008, RemeGen is committed to the discovery, development and commercialization of innovative biologics to provide safe and effective clinical treatment options
for patients in the fields of autoimmune diseases, oncology, ophthalmology and other diseases.
According to the official website of Remegen, the company has developed more than 20 candidate biologic products
.
Among them, two innovative drugs have been approved for marketing, namely: BLyS/APRIL dual-target fusion protein innovative drug Tatanercept, which has been approved by the National Food and Drug Administration (NMPA) of China in March 2021 for the treatment of systemic lupus erythematosus; Vedicitumab, an antibody conjugate drug (ADC) targeting HER2, has been approved for two indications in China for the treatment of
gastric cancer and urothelial cancer.

The company has developed more than 20 biologic product candidates, including two innovative drugs approved for the marketing of tataceptvisitumab

Faith Medicine

Presentation: January 1, 11:4 p.
m.
PT

Presentation time: January 11, 4:30 p.
m.
Pacific Time, United States of America afternoon

Belief Medicine (Belief Founded in 2018, BioMed is committed to providing more effective and innovative gene therapies
for genetic defective genetic diseases, neurodegenerative diseases, age-related degenerative diseases, and some major malignant diseases through safe and efficient adeno-associated virus (AAV) vector technology.
The AAV gene therapy drug BBM-H901 injection developed by the company has been approved for clinical trials in China and has been included in the breakthrough therapy variety by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, and is intended to be used to prevent bleeding
in adult male patients with hemophilia B.
In addition, the drug has been granted orphan drug status by the US FDA for the treatment of hemophilia B
.
In December 2022, BBM-H803 injection, another AAV gene therapy drug developed by the company, was also granted orphan drug designation by the FDA for the treatment of hemophilia A
.

To provide more effective innovative gene therapy BBM-H901 injection for gene defects, genetic diseases, neurodegenerative diseases, age-related degenerative diseases and some major malignant diseases, it is planned to prevent bleeding in adult male patients with hemophilia B, and BBM-H803 injection is used to treat hemophilia A

Junshi Biotechnology

Presentation: January 1, 11:4 p.
m.
PT

Presentation time: January 11, 4:30 p.
m.
Pacific Time, United States of America afternoon

Junshi Biosciences Founded in December 2012, it is dedicated to the discovery, development and commercialization
of innovative therapies.
According to the official website of Junshi Biologics, the company has established a product pipeline consisting of 50+ products under development, covering five major therapeutic areas
: malignant tumors, autoimmune system diseases, chronic metabolic diseases, neurological diseases and infectious diseases.

The company has built a pipeline of 50+ products in development

At present, the anti-PD-1 monoclonal antibody teripulimab developed by Junshi Biologics has been approved for 6 indications in China, involving melanoma, nasopharyngeal carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, and non-small cell lung cancer
.
In addition, the drug has also submitted marketing applications
to the US FDA, the European Medicines Agency (EMA), and the UK Medicines and Healthcare Products Agency (MHRA).
In addition, the adalimumab biosimilar jointly developed by Junshi Biologics and Mabwell was also approved in China in 2022 , for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, children's plaque psoriasis, children's Crohn's disease and other indications
.

Teripulimab has been approved in China for 6 indications adalimumab biosimilars

Keyue Pharma Presentation Time: January 12, 9:00 a.
m.
Pacific TimeSpeaker: CEO of Keyue Pharmaceutical Dr.
Frederick Beddingfield

Keyue Medicine (Kira Pharma) was founded in 2017 to develop complement-targeted therapies for the treatment of immune-mediated diseases
.
With its LOGIC drug discovery platform, Keyue Pharma is committed to developing "first-in-class" and potentially "best-in-class" complement therapies to change patients' lives
.
According to a press release from Keyue Pharmaceutical, the CEO of the company Dr.
Frederick Beddingfield will speak
on Thursday, January 12, 2023 at 9 a.
m.

He is committed to the research and development of complement-targeted therapies for the treatment of immune-mediated diseases

According to the official website of Keyue Pharmaceutical, the company has established a product pipeline
containing multiple drug candidates.
Among them, the dual-target complement biologics KP104 developed by the company have been approved for Phase 2 clinical trials in China and Australia for kidney diseases including IgA nephropathy and C3 glomerulopathy, and have been approved for Phase 2 clinical trials
in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
In addition, the drug has been approved by the FDA for a Phase 2 clinical trial for the treatment of thrombotic microangiopathy associated with systemic lupus erythematosus, and has been granted orphan drug designation
by the FDA for PNH indications.

Dual-target complement biologics

Boosin

Founded in 2017, BIOSION is committed to developing innovative therapies for immunological and oncology diseases using a proprietary antibody technology platform, and the founder, chairman and CEO of BIOSION is Dr.

Chen Mingjiu.
Currently, the company has built a portfolio of innovative drugs through an in-house proprietary technology platform
.
Among them, the anti-TSLP monoclonal antibody BSI-045B has entered phase 2 clinical trials in China, and will soon launch global phase 2 clinical trials
in the United States in early 2023, including atopic dermatitis.
In addition, the company has several product candidates planned to enter clinical trials
in the United States and China within the next year.

Dr.
Mingjiu Chen's anti-TSLP monoclonal antibody BSI-045B has entered Phase 2 clinical trials in China

Tianchen Creatures

LongBio focuses on the research and development of innovative macromolecular drugs for autoimmune diseases such as allergies and rare diseases, and the co-founders of the company are Dr.
Heng Liu and Dr.

Naichao Sun.
At present, the company has built a number of next-generation macromolecular antibodies
with potential differentiation advantages.
Among them, the core project of the new generation of anti-IgE antibody LP-003 is expected to start phase 2 clinical trials at the end of the first quarter of 2023, and the other core project is the complement bifunctional inhibitor LP-005, which is scheduled to submit an IND application
in the first quarter of 2023.

Dr.
Heng Liu, Dr.
Naichao Sun, a new generation of anti-IgE antibody LP-003 complement bifunctional inhibitor LP-005,

Bichen Pharmaceutical

BICHEN Pharmaceuticals (ABM Therapeutics) was founded in 2015, focusing on the development of small molecule drugs that can break through the blood-brain barrier, the founder and CEO of the company is Dr.
Chen Chen, and the co-founder and COO is Mr.

Huang Qing.
Through its transcerebral kinase drug discovery platform, Pichen has established a rich pipeline of in-brain drug development, and intends to develop indications focused on cancers with high incidence of brain metastases, including melanoma, lung cancer, colorectal cancer, etc
.
At present, Bichen has two self-developed products approved for clinical trials in the United States, namely ABM-1310, a small molecule BRAF inhibitor with high blood-brain barrier permeability, and ABM-168
, a MEK1/2 inhibitor that can enter the brain.

Dr.
Chen Chen, Dr.
Huang Qing, high blood-brain barrier permeable small molecule BRAF inhibitor can enter the brain MEK1/2 inhibitor

I-Mab Creatures

I-Mab (I-Mab Biopharma focuses on the development, manufacturing and commercialization
of innovative or highly differentiated biologics in the field of tumor immunity and autoimmunity.
According to I-Mab's website, the company's core products include differentiated CD38 monoclonal antibody finzetumab, innovative CD47 monoclonal antibody lezolimab, differentiated CD73 monoclonal antibody ulezalimab, and innovative Claudin 18.
2 x 4-1BB bispecific antibody TJ-CD4B, differentiated long-acting growth hormone etan growth hormone, etc
.
According to I-Mab's 2022 first-half performance report, the company has 5 core clinical stage products and 10 clinical research projects, of which 3 products are expected to be gradually submitted to Biologics License (BLA) and launched within
3 years.

Differentiated CD38 monoclonal antibody innovation CD47 monoclonal antibody differentiated CD73 monoclonal antibody innovation Claudin 18.
2 x 4-1BB bianti-long-acting growth hormone

Laekna Pharmaceutical

Founded in 2016 to bring breakthrough therapies to cancer and liver fibrosis patients worldwide, Laekna is developing
14 innovative product candidates in its pipeline 。 At present, Laekna has two potential core products: LAE002, a highly selective ATP-competitive AKT inhibitor that is being developed for the treatment of ovarian, prostate, breast cancer and solid tumors resistant to PD-1/PD-L1 therapy; The other is LAE001, a next-generation androgen synthesis inhibitor that simultaneously inhibits CYP17A1 and CYP11B2, and is being developed for the treatment of prostate cancer
.
According to the press release of Laekna Pharma, Dr.
Lu Xiangyang, chairman and CEO of the company, will attend the JPM conference
.

One is LAE002, which is a highly selective ATP-competitive AKT inhibitor, and the other is LAE001, a next-generation androgen synthesis inhibitor, and Dr.
Lu Xiangyang, chairman and CEO of the company, will attend the JPM conference

In addition to the above companies, many other Chinese biopharmaceutical companies will also be present at this year's JPM conference
.
Due to space limitations, this article will not introduce
them all.

JPM is one of the world's largest conferences on medical investment, industry exchange and cooperation in the field of biomedical health, covering the entire global healthcare field
.
We will continue to follow the progress of this JPM conference and share more recent developments and developments
from biomedical companies.

Resources:

[1] J.
P.
Morgan.
Retrieved Jan 10, 2023, From

[1] J.
P.
Morgan.
Retrieved Jan 10, 2023, From [2] Official websites, press releases and public information of each company

[2] Official websites, press releases and public information of each company

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.